PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS

INTRO: Oral antiviral agents with differing modes of action are now available for the treatment of COVID-19. However, potentially life-threatening drug-drug interactions (DDIs) may occur if patients’ underlying co-morbidities are treated with medications that are contraindicated with ritonavir-conta...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, C., Chen, W.-T., Tan, W.-H., Chen, Y., Lam, C., Igho-Osagie, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186947/
http://dx.doi.org/10.1016/j.ijid.2023.04.221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186947/
http://dx.doi.org/10.1016/j.ijid.2023.04.221

Ejemplares similares